{
    "root": "11b7dcc4-7810-4ecd-b203-3dc5d350743b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Adalimumab",
    "value": "20241121",
    "ingredients": [
        {
            "name": "ADALIMUMAB",
            "code": "FYS6T7F842"
        },
        {
            "name": "ADIPIC ACID",
            "code": "76A0JE0FKJ"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "adalimumab-adaz tumor necrosis factor ( tnf ) -blocker indicated : • rheumatoid arthritis ( rheumatoid arthritis ) ( 1.1 ) : reducing signs symptoms , inducing major response , inhibiting progression structural damage , improving physical function adult patients moderately severely active rheumatoid arthritis . • juvenile idiopathic arthritis ( jia ) ( 1.2 ) : reducing signs symptoms moderately severely active polyarticular jia patients 2 years age older . • psoriatic arthritis ( psa ) ( 1.3 ) : reducing signs symptoms , inhibiting progression structural damage , improving physical function adult patients active psa . • ankylosing spondylitis ( ) ( 1.4 ) : reducing signs symptoms adult patients active . • crohn ’ disease ( cd ) ( 1.5 ) : treatment moderately severely active crohn ’ disease adults pediatric patients 6 years age older . • ulcerative colitis ( uc ) ( 1.6 ) : treatment moderately severely active ulcerative colitis adult patients . limitations : effectiveness established patients lost response intolerant tnf blockers . • plaque psoriasis ( ps ) ( 1.7 ) : treatment adult patients moderate severe chronic plaque psoriasis candidates systemic therapy phototherapy , systemic therapies medically less appropriate . • hidradenitis suppurativa ( hs ) ( 1.8 ) : treatment moderate severe hidradenitis suppurativa adult patients . • uveitis ( uv ) ( 1.9 ) : treatment non-infectious intermediate , posterior , panuveitis adult patients .",
    "contraindications": "• administer subcutaneous injection ( 2 ) rheumatoid arthritis , psoriatic arthritis , ankylosing spondylitis ( 2.1 ) : • adults : 40 mg every week . • patients rheumatoid arthritis receiving methotrexate may benefit increasing 40 mg every week 80 mg every week . juvenile idiopathic arthritis ( 2.2 ) : pediatric weight 2 years age older recommended 10 kg ( 22 lbs ) less 15 kg ( 33 lbs ) 10 mg every week 15 kg ( 33 lbs ) less 30 kg ( 66 lbs ) 20 mg every week 30 kg ( 66 lbs ) greater 40 mg every week crohn 's disease ( 2.3 ) : • adults : 160 mg day 1 ( given one day split two consecutive days ) ; 80 mg day 15 ; 40 mg every week starting day 29 . • pediatric patients 6 years age older : pediatric weight recommended days 1 15 starting day 29 17 kg ( 37 lbs ) less 40 kg ( 88 lbs ) day 1 : 80 mg day 15 : 40 mg 20 mg every week 40 kg ( 88 lbs ) greater day 1 : 160 mg ( single dose split two consecutive days ) day 15 : 80 mg 40 mg every week ulcerative colitis ( 2.4 ) : • adults : 160 mg day 1 ( given one day split two consecutive days ) , 80 mg day 15 40 mg every week starting day 29. discontinue patients without evidence remission eight weeks ( day 57 ) . plaque psoriasis adult uveitis ( 2.5 ) : • adults : 80 mg initial dose , followed 40 mg every week starting one week initial dose . hidradenitis suppurativa ( 2.6 ) : • adults : • day 1 : 160 mg ( given one day split two consecutive days ) • day 15 : 80 mg • day 29 subsequent doses : 40 mg every week 80 mg every week",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "Adalimumab-adaz is a tumor necrosis factor (TNF)-blocker indicated for: • Rheumatoid Arthritis (RA) (1.1) : reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) (1.2) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) (1.3) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) (1.4) : reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) (1.5) : treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ) : treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ) : treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.",
    "contraindications_original": "• Administer by subcutaneous injection (2) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1) : • Adults: 40 mg every other week. • Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week. Juvenile Idiopathic Arthritis (2.2) : Pediatric Weight 2 Years of Age and Older Recommended Dosage 10 kg (22 lbs) to less than 15 kg (33 lbs) 10 mg every other week 15 kg (33 lbs) to less than 30 kg (66 lbs) 20 mg every other week 30 kg (66 lbs) and greater 40 mg every other week Crohn's Disease (2.3 ): • Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29. • Pediatric Patients 6 Years of Age and Older: Pediatric Weight Recommended Dosage Days 1 and 15 Starting on Day 29 17 kg (37 lbs) to less than 40 kg (88 lbs) Day 1: 80 mg Day 15: 40 mg 20 mg every other week 40 kg (88 lbs) and greater Day 1: 160 mg (single dose or split over two consecutive days) Day 15: 80 mg 40 mg every other week Ulcerative Colitis (2.4 ): • Adults : 160 mg on Day 1 (given in one day or split over two consecutive days), 80 mg on Day 15 and 40 mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57). Plaque Psoriasis or Adult Uveitis ( 2.5 ): • Adults : 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose. Hidradenitis Suppurativa ( 2.6 ): • Adults: • Day 1: 160 mg (given in one day or split over two consecutive days) • Day 15: 80 mg • Day 29 and subsequent doses: 40 mg every week or 80 mg every other week",
    "adverseReactions_original": "None."
}